Transcranial ultrasound holds much potential as a safe, non-invasive modality for navigated neuromodulation, with low-intensity focused ultrasound (FUS) and transcranial pulse stimulation (TPS) representing the two main modalities. While neuroscientific and preclinical applications have received much interest, clinical applications are still relatively scarce. For safety considerations, the current literature is largely based on guidelines for ultrasound imaging that uses various physical parameters to describe the ultrasound pulse form and expected bioeffects. However, the safety situation for neuromodulation is inherently different. This article provides an overview of relevant ultrasound parameters with a focus on bioeffects relevant for safe clinical applications. Further, a retrospective analysis of safety data for clinical TPS applications in patients is presented.
Background: Novel ultrasound neuromodulation techniques allow therapeutic brain stimulation with unmet precision and non-invasive targeting of deep brain areas. Transcranial pulse stimulation (TPS), a multifrequency sonication technique, is approved for the clinical treatment of Alzheimer’s disease (AD). Here, we present the largest real-world retrospective analysis of ultrasound neuromodulation therapy in dementia (AD, vascular, mixed) and mild cognitive impairment (MCI). Methods: The consecutive sample involved 58 patients already receiving state-of-the-art treatment in an open-label, uncontrolled, retrospective study. TPS therapy typically comprises 10 sessions (range 8–12) with individualized MRI-based target areas defined according to brain pathology and individual pathophysiology. We compared the CERAD-Plus neuropsychological test battery results before and after treatment, with the CERAD Corrected Total Score ( CTS) as the primary outcome. Furthermore, we analyzed side effects reported by patients during the treatment period. Results: CERAD Corrected Total Score (CTS) significantly improved (p = .017, d = .32) after treatment (Baseline: M = 56.56, SD = 18.56; Post-treatment: M = 58.65, SD = 19.44). The group of top-responders (top quartile) improved even by 9.8 points. Fewer than one-third of all patients reported any sensation during treatment. Fatigue and transient headaches were the most common, with no severe adverse events. Conclusions: The findings implicate TPS as a novel and safe add-on therapy for patients with dementia or MCI with the potential to further improve current state-of-the-art treatment results. Despite the individual benefits, further randomized, sham-controlled, longitudinal clinical trials are needed to differentiate the effects of verum and placebo.
23 August 2024 in The Journals of Gerontology, Series B: Psychological Sciences and Social Sciences
We investigate how adults of different ages experience changes in their social relationships during significant life events. Based on different goal priorities, younger adults may benefit more from establishing new social contacts during a significant life event, whereas older adults may benefit more from maintaining existing relationships. To test these hypotheses, we conducted multilevel modeling with a sample of N = 6,688 participants aged 18–90 years who reported at least 1 significant life event in the past 2 years. Both establishing new social relationships and maintaining existing relationships during significant life events were associated with higher levels of well-being. As predicted, these associations were moderated by age. Establishing new social relationships was more strongly associated with mental health and life satisfaction in younger adults, whereas maintaining existing relationships was more strongly associated with subjective well-being, physical health, and loneliness in older adults. These findings provide valuable insights into the role of age in the change and stability of social relationships during significant life events.
This study examines whether there are age-related differences in the experience of life events across adulthood. We hypothesized that older adults would report life events that are less anticipated, less normative, less controllable, less positive, and more strenuous than younger adults due to increasing developmental losses and decreasing gains. We investigated how age (linear, quadratic, and cubic) relates to life-event characteristics by comparing different events and analyzing the same events across individuals, to distinguish between the effects observed across life events and those that emerge after accounting for the specific life event in question. Additionally, we hypothesized that older adults would cope better with less favorable events due to their life experience and emotion regulation skills. Analyses of 6,688 participants (18–90 years) showed that while older adults reported less favorable life events, they coped better with the same events than younger adults. The results underscore the importance of distinguishing between age and life event effects. They also show that life-event characteristics are consistently linked to well-being throughout adulthood.
Background: Depression is a common comorbidity in neuropsychiatric disorders, affecting a significant proportion of patients with neurodegenerative diseases. Traditional antidepressants show limited efficacy, particularly in cases involving comorbid depressive symptoms, highlighting the need for alternative treatments. Methods: Here we provide the first data on possible benefits of add-on therapy with transcranial pulse stimulation (TPS). Based on the largest patient sample in the emerging field of focused ultrasound (FUS) neuromodulation to date, a retrospective analysis was conducted on 88 patients with various neuropsychiatric diagnoses to evaluate the impact of TPS on depressive symptoms, measured by the Beck Depression Inventory (BDI-II). Results: The study revealed significant improvements in BDI-II scores posttreatment ( N = 88), with the most substantial effects observed in more severely impacted patients: individuals with minimal to severe depression (BDI-II ≥9; N = 32) experienced an average reduction of 5.22 points (29.46%), while those with mild to severe depression (BDI-II ≥14; N = 15) showed an even greater mean improvement of 10.40 points (40.51%). These results surpassed established thresholds for clinical relevance and substantially exceeded placebo effect sizes observed in relevant brain stimulation studies. Moreover, depression score improvement was independent of diagnostic group (dementia, movement disorders, or other), improvement of the primary diagnosis, antidepressant medication, and baseline cognitive status, highlighting the potential of TPS as an effective therapeutic add-on intervention for patients receiving state-of-the-art treatments. Conclusions: The study’s findings indicate that TPS enhances depression outcomes in neuropsychiatric patients, particularly in those with more severe depressive symptoms.
The COVID-19 pandemic represents a context that might influence how people experience significant life events (such as marriage, job change, or relocation). In the present research, we argue that one important factor of how positively or negatively the pandemic influences the experience of significant life events is how much control people perceive in the situation. An online sample of N = 882 participants aged 18–82 years reported a significant life event that occurred during the COVID-19 pandemic. The participants described whether the pandemic influenced the life event, to what extent they perceived control over the life event and how they experienced the life event in terms of valence (i.e., positively or negatively). The results showed that the self-reported pandemic influence was significantly associated with the life-event experience. Furthermore, perceived control partly mediated this association. The results persisted even after controlling for the age of the participants. The present research underscores the important role of control for experiencing significant life events in challenging times such as during the pandemic.